37
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Establishment of Hybrid Cell Lines Producing Monoclonal Antibodies to a Synthetic Peptide from the E1 Region of the Hepatitis C Virus

, , , , , & show all
Pages 91-104 | Received 27 Mar 2007, Accepted 01 Aug 2007, Published online: 31 Dec 2007
 

Abstract

We aimed at establishing hybridoma cells secreting monoclonal antibodies (mAbs) against E1 synthetic peptide of HCV. BALB/c mice were immunized with HCV E1‐synthetic peptide (GHRMAWDMM) and its spleenocytes were fused with the P3NS1 myeloma cell line. Two highly reactive and specific mAbs (10C7 IgG2b mAb, and 10B2 IgG1 mAb) were generated. The target HCV E1 antigen was identified at ∼38 kDa in serum of infected individuals. A newly developed ELISA detected the target antigen in 90% of sera from HCV RNA infected individuals with a specificity of 84%. So, the generated mAbs may provide promising probes for serodiagnosis of HCV infection.

Acknowledgments

The authors would like to thank Yasmine S. El‐Abd at NRC for her kind help. The present work is supported in part by Ministry of Scientific Research, Academy of Scientific Research & Technology (Medical Research Council Code: P5‐MED‐030‐01), and National Strategy for Genetic Engineering and Biotechnology Projects, Egypt.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 61.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.